Co-founder, Stealth Startup | Fmr. Director, Data
Science @ Johnson and Johnson

• Oscar has led AI strategic initiatives and product development across
  Fortune 50 (Johnson & Johnson) and VC-backed biotech (PathAI)
  companies, bringing a unique lens into the rapidly changing ecosystem of AI
  for life sciences. Oscar has expertise in AI product strategy, pharma-tech
  partnering, AI startup diligence, and validation and regulatory strategies.
  Oscar is also passionate about startups and participating in Accelerators and
  Incubators within the Cambridge / Boston community.

Experience in AI strategy

• Oscar holds a PhD in Biomedical Engineering and has conducted AI research
  in industry and academia, including at MIT and Duke. Collectively, Oscar’s
  research has produced 130+ articles and presentations in top-tier journals
  (eg Nature Medicine, Nature Comms) as well as technical and clinical
  conferences. Oscar’s experience includes AI/ML (computer vision,
  generative AI, foundational models) in biopharma R&D and diagnostics
  across multiple diseases (ONC, IMM, CVM, ophthalmology).

Prior research

Dr. Oscar Carrasco-Zevallos

• Strategy

Insights | Thoughts and analyses on the ever-changing AI ecosystem

• Technology

• VC & start-ups

Opinions and content are my own and do not reflect the views of my employer.

• Under construction!

• Business value of data in the era
  of AI foundation models

• Will OpenAI kill my start-up? A
  survival handbook

• The transformative potential of
  multimodal AI in healthcare

• Target ID
• Biomarker discovery
• Image analysis

• Patient selection
• Digital endpoints
• Regulatory strategy

• Research
• Development and
  feasibility testing

• Clinical validation
• Regulatory strategy
  & design control

Drug Development

Medical Device Development

Portfolio | Prior work using AI to accelerate medical product R&D

Featured
Case Studies

Target ID via transcriptomic analysis

Automated assessment of trial endpoints

Phenotypic analysis in animal models

Real-time image guided surgery

• 2022 - J&J Innovation Medicine R&D SPARK Innovation Award for groundbreaking strategies and platforms, J&J
• 2021 - Invited plenary presentation at FNIH Biomarkers Consortium Metabolic Disorders Meeting, PathAI
• 2020 - Selected for “100 Inspiring Hispanic Scientists in America,” Cell Press, PathAI
• 2019 - 1st place, Harvard-MIT Case Competition, MIT
• 2018 - National Institutes of Health NRSA F32 Individual Postdoctoral Fellowship, MIT
• 2018 - Burroughs Wellcome Fund Postdoctoral Enrichment Program Award, MIT
• 2018 - Leadership Award for Outstanding Service, Duke University
• 2017 - MIT’s Rising Star in Biomedical, MIT
• 2012 - National Science Foundation Graduate Research Fellowship, Duke University
• 2012 - Ford Foundation Predoctoral Fellowship, Duke University
• 2011 - Best Undergraduate Honors Research Thesis, Texas A&M
• 2011 - Craig C. Brown Outstanding Senior Engineer Award, Texas A&M
• 2011 to current - 10+ awards and distinctions for research presented at leading medical and technical conferences

• 2022 - Paige, Janssen team up to launch AI-powered bladder cancer test: Fierce Biotech
• 2021 - Acceptance of AI drug development tool into FDA biomarker qualification program: PR Newswire
• 2021 - Oral presentation on AI-based drug development tool: PR Newswire
• 2017 - Intraoperative Optical Coherence Tomography feature: Retina Today article

Notable Awards

Press

Select Publications and Presentations (from 130+)

• J. Iyer, ... O. M. Carrasco-Zevallos, … A. H. Beck, “AI-based automation of enrollment criteria and endpoint assessment in clinical trials in liver diseases,” Nature
  Medicine, 2024. Link to publication
• A. J. Ramon, C. Parmar, O. M. Carrasco-Zevallos … K. Standish, “Development and real-time deployment of a histopathology-based deep learning algorithm for
  patient pre-screening in a targeted-therapy bladder cancer clinical trial,” Nature Communications, 2024. Link to publication
• B. Lutnick, … O. M. Carrasco-Zevallos, S. S. F. Yip, “A user-friendly AI system for histopathology image analysis system to accelerate pharmaceutical R&D,”
  Journal of Pathology Informatics, 2023. Link to publication
• J. Conway*, M. Pouryahya* … O. M. Carrasco-Zevallos … C. Chung, “Integration of Deep Learning-Based Histopathology with Transcriptomics Identifies Key
  Genes Associated with Fibrogenesis in Patients with Advanced NASH,” Cell Reports Medicine, 2023. *Authors contributed equally. Link to publication
• M. Carrasco-Zevallos, … K. Wack, “AI-based histologic measurement of NASH (AIM-NASH): A drug development tool for assessing clinical trial endpoints,” EASL
  International Liver Congress, 2021. Oral presentation. Link to presentation
• C. Shukla, O. M. Carrasco-Zevallos, …J. E. Gane, “Machine learning enables quantitative assessment of histopathologic signatures associated with ALT
  normalization in chronic hepatitis B patients treated with tenofovir disoproxil fumarate (TDF),” AASLD, Boston, USA, 2020. Plenary oral presentation. Link to
  presentation

• O. M. Carrasco-Zevallos, AI-enabled devices to accelerate drug development, Bioengineering Seminar Series, UIUC, 2022.
• O. M. Carrasco-Zevallos*, Asha Mahesh*, ML-Enabled Biomarkers for Clinical Trials: A Framework for Productization and Deployment, Bio-IT World, Boston, MA
  2022. *Co-presenters
• O. M. Carrasco-Zevallos, “AI-based assessment of NASH histology for treatment monitoring and risk stratification,” FNIH Biomarkers Consortium Metabolic
  Disorders Meeting, Plenary Session, Webinar 2021.
• O. M. Carrasco-Zevallos, “AI-powered computational pathology for liver diseases,” HBV Liver Forum – Intrahepatic Panel, The Forum for Collaborative Research,
  Webinar, 2020. Link to presentation

Invited Talks (from 10+)

Coming soon!